By Ellen ‘t Hoen, Global Health Unit Department of Health Sciences, UMCG Groningen, email@example.com
The movement to delink the cost of developing medicines from their market price received another boost this week, with the publication of a new report from the Netherlands Council for Public Health and Society, an official government advisory body.
This report is part of a recent phenomenon in which even the wealthiest of health systems have been unable to afford medicines developed under a monopoly-based pharmaceutical innovation model, and underlines a growing international consensus that better models to incentivise the creation of new medicines are needed. High priced medicines resulting from this model cause access problems and are a threat to the affordability of health care in almost all European countries. Medical professionals and patients are calling on their governments to take action.